# A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

> **NCT02588625** · PHASE2 · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Scleroderma

## Interventions

- **DRUG:** BMS-986020
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02588625
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-02
- **Primary completion:** 2019-10
- **Final completion:** 2019-10
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02588625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02588625, "A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02588625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*